MedTrace Logo

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

NCT03743376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-05-13

No results posted yet for this study

Summary

This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients

Conditions

  • HIV-1 Infection

Interventions

BIOLOGICAL

UB-421(25 mg/kg) Q2W

Monoclonal antibody by IV infusion plus standard ART

BIOLOGICAL

UB-421(25 mg/kg) Q4W

Monoclonal antibody by IV infusion plus standard ART

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Taoyuan General Hospital

    collaborator OTHER_GOV

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    collaborator OTHER

  • Kaohsiung Veterans General Hospital.

    collaborator OTHER

  • United BioPharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2020-10-15
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03743376 on ClinicalTrials.gov